Bristol-Myers Squibb Company Stock

BMY

US1101221083

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 04:00:35 2024-05-14 pm EDT			5-day change	1st Jan Change
44.66 ^USD	-0.89%		+1.70%	-12.71%

May. 10	Bristol-Myers Squibb Says Phase 3 Trial of Opdivo in Lung Cancer Fails to Meet Primary Endpoint	MT
May. 10	Bristol Myers Squibb Cancer-Treatment Trial Misses Endpoint	DJ

on all our subscriptions*

Last Days!

Take advantage of the offer

* See conditions on site

Chart Bristol-Myers Squibb Company

Duration

Period

Style

Dynamic Chart

Latest news about Bristol-Myers Squibb Company

Bristol-Myers Squibb Says Phase 3 Trial of Opdivo in Lung Cancer Fails to Meet Primary Endpoint	May. 10	MT
Bristol Myers Squibb Cancer-Treatment Trial Misses Endpoint	May. 10	DJ
Bristol Myers Squibb Provides Update on Phase 3 CheckMate -73L Trial	May. 10	CI
India's Cipla open to partnering with Eli Lilly to market their obesity drugs, CEO says	May. 10	RE
Declaration of Voting Results by Bristol-Myers Squibb Company	May. 09	CI
Declaration of Voting Results by Bristol-Myers Squibb Company	May. 09	CI
India's Alembic Pharma posts higher Q4 profit on strong N.America sales	May. 09	RE
Ligand Pharmaceuticals Investing in Agenus to Fund Development of Oncology Drug Candidates	May. 07	MT
Top Midday Stories: Tyson Shares Tumble on Earnings Miss; Robinhood Receives Wells Notice From SEC Staff; Spirit Airlines to Furlough up to 260 Pilots; Shell in Talks to Sell Malaysian Gas Station Business to Saudi Aramco	May. 06	MT
Bristol-Myers Squibb Says Applications for Opdivo Accepted by US, European Regulators	May. 06	MT
Bristol-Myers Gets FDA Acceptance of Review for Subcutaneous Opdivo Formulation	May. 06	DJ
Bristol-Myers: BLA accepted for subcutaneous Opdivo	May. 06	CF
U.S. Food and Drug Administration Accepts Bristol Myers Squibb?s Application for Subcutaneous Nivolumab (nivolumab and hyaluronidase)	May. 06	CI
European Medicines Agency Validates Bristol Myers Squibb?s Application for Opdivo Plus Yervoy for the First-Line Treatment of Adult Patients with Microsatellite Instability?High or Mismatch Repair Deficient Metastatic Colorectal Cancer	May. 06	CI
HSBC Adjusts Price Target on Bristol-Myers Squibb to $45 From $50	May. 01	MT

More news

Latest transcript on Bristol-Myers Squibb Company

Bristol-Myers Squibb Company, Q1 2024 Earnings Call, Apr 25, 2024

Apr. 25

More transcripts

Analyst Recommendations on Bristol-Myers Squibb Company

HSBC Adjusts Price Target on Bristol-Myers Squibb to $45 From $50	May. 01	MT
ANALYST RECOMMENDATIONS : Tesla, Snap, Alphabet, Microsoft, Anglo American...	Apr. 30
Goldman Sachs Cuts Bristol-Myers Squibb's Price Target to $56 From $60	Apr. 29	MT
Deutsche Bank Adjusts Price Target on Bristol-Myers Squibb to $53 From $55, Keeps Hold Rating	Apr. 29	MT
Leerink Partners Cuts Price Target on Bristol-Myers Squibb to $47 From $51	Apr. 26	MT

More recommendations

Press releases Bristol-Myers Squibb Company

Bristol Myers Squibb Provides Update on Phase 3 CheckMate -73L Trial	May. 10	BU
Bristol Myers Squibb to Participate in Upcoming Investor Conferences	May. 07	BU
U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Application for Subcutaneous Nivolumab (nivolumab and hyaluronidase)	May. 06	BU
European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite...	May. 06	BU
Repertoire® Immune Medicines and Bristol Myers Squibb Announce Multi-Year Strategic Collaboration to Develop Tolerizing Vaccines for Autoimmune Diseases	Apr. 29	PR

More press releases

News in other languages on Bristol-Myers Squibb Company

Bristol-Myers : un BLA admis pour Opdivo sous-cutané	May. 06
Malgré un fort recul lié aux soins anti-Covid, Pfizer relève ses prévisions	May. 01
RECOMENDACIONES DE LOS ANALISTAS EE.UU./UK : Tesla, Snap, Alphabet, Microsoft, Anglo American...	Apr. 30
Après Microsoft, Alphabet, Tesla et Apple, Amazon doit faire le job	Apr. 30
En Direct des Marchés : Thales, Stellantis, Capgemini, Atos, VusionGroup, Orpea, Adidas, HSBC...	Apr. 30

More news

Highs and lows

1 week

43.50

45.32

1 month

43.33

49.56

Current year

43.33

55.04

1 year

43.33

68.46

3 years

43.33

81.44

5 years

42.48

81.44

10 years

42.48

81.44

More quotes

Managers and Directors - Bristol-Myers Squibb Company

Managers	Title	Age	Since
Christopher Boerner CEO	Chief Executive Officer	53	15-01-31
David Elkins DFI	Director of Finance/CFO	55	19-11-19
Greg Meyers CTO	Chief Tech/Sci/R&D Officer	-	-

Members of the board	Title	Age	Since
Phyllis Yale BRD	Director/Board Member	66	19-11-19
Peter Arduini BRD	Director/Board Member	59	16-03-31
Derica Rice BRD	Director/Board Member	59	20-08-31

More insiders

ETFs positioned on Bristol-Myers Squibb Company

Name	Weight	AuM	1st Jan change	Investor Rating
AGF U.S. MARKET NEUTRAL ANTI-BETA FUND - USD	12.97%	254 M€	+11.45%	-
BMO MSCI GENOMIC INNOVATION INDEX ETF - CAD	4.99%	2 M€	-.--%
NOMURA NEXT FUNDS INTERNATIONAL EQUITY MSCI-KOKUSAI (YEN-HEDGED) ETF - JPY	4.01%	17 M€	+6.46%	-

More ETFs positioned on Bristol-Myers Squibb Company

Quotes

Date	Price	Change	Volume
24-05-14	44.78	-0.61%	9 375 016
24-05-13	45.06	+0.27%	12,642,469
24-05-10	44.94	+0.45%	8,699,595
24-05-09	44.74	+2.45%	10,776,314
24-05-08	43.67	-0.84%	11,928,339

Delayed Quote Nyse, May 13, 2024 at 04:00 pm EDT

More quotes

Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques. The United States account for 70.1% of net sales.

Sector

Pharmaceuticals

Calendar

2024-05-15 - BofA Securities Health Care Conference

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Christopher Boerner, CEO of Bristol-Myers: A pipeline of 16 treatments, with a focus on neuroscience and oncology

January 09, 2024 at 01:06 pm EST

More Strategies

Ratings for Bristol-Myers Squibb Company

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

45.06 USD

Average target price

53.19 USD

Spread / Average Target

+18.05%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
BRISTOL-MYERS SQUIBB COMPANY	-12.18%	91.34B
ELI LILLY AND COMPANY	+29.98%	682B
NOVO NORDISK A/S	+30.34%	586B
JOHNSON & JOHNSON	-3.52%	364B
MERCK & CO., INC.	+18.59%	327B
ABBVIE INC.	+4.07%	285B
ASTRAZENECA PLC	+16.21%	240B
NOVARTIS AG	+9.66%	209B
ROCHE HOLDING AG	-6.83%	203B
AMGEN INC.	+7.09%	165B

Other Pharmaceuticals

Sales 2024 *	46.02B	Sales 2025 *	46.16B	Capitalization	91.34B
Net income 2024 *	-5.4B	Net income 2025 *	10.22B	EV / Sales 2024 *	2.84 x
Net Debt 2024 *	39.2B	Net Debt 2025 *	31.85B	EV / Sales 2025 *	2.67 x
P/E ratio 2024 *	-17.2 x	P/E ratio 2025 *	8.51 x	Employees	34,100
Yield 2024 *	5.34%	Yield 2025 *	5.61%	Free-Float	69.27%

1 day	+0.27%
1 week	+2.64%
Current month	+2.55%
1 month	-6.67%
3 months	-7.49%
6 months	-10.15%
Current year	-12.18%

Bristol-Myers Squibb Company Stock

Equities

BMY

US1101221083

Pharmaceuticals

Financials (USD)

Chart Bristol-Myers Squibb Company

Latest news about Bristol-Myers Squibb Company

Latest transcript on Bristol-Myers Squibb Company

Analyst Recommendations on Bristol-Myers Squibb Company

Press releases Bristol-Myers Squibb Company

News in other languages on Bristol-Myers Squibb Company

Quotes and Performance

Highs and lows

Managers and Directors - Bristol-Myers Squibb Company

ETFs positioned on Bristol-Myers Squibb Company

Quotes

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Bristol-Myers Squibb Company

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals